PR Newswire: news distribution, targeting and monitoring
2014

BioLineRx Reports Second Quarter 2013 Results

Share with Twitter Share with LinkedIn

JERUSALEM, Aug. 6, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

Recent Highlights:

  • BL-1040 (ventricular remodeling) – The PRESERVATION I clinical trial, a CE-Mark registration trial, is proceeding as scheduled – there are currently 36 active sites in 9 countries, including 7 leading sites in the U.S. 
  • BL-5010 (skin lesions) – The necessary regulatory submissions to commence a pivotal, CE-Mark registration trial in Europe have been filed; the CRO and three sites in Germany have been selected. 
  • BL-8040 (AML) – The ongoing Phase 2 clinical trial is progressing as planned, and currently has 6 active sites recruiting (out of 8 sites in total); the first patient was enrolled in the study at the MD Anderson Cancer Center in Houston; Northwestern Memorial Hospital in Chicago was recently initiated into the trial and is expected to commence recruitment in the coming weeks; enrollment has been initiated at several leading sites in Israel following approval from the Israeli Ministry of Health;
  • BL-7010 (celiac disease) - Advanced GLP toxicology studies have begun and the CRO and sites in Europe have been selected for the upcoming Phase 1/2 clinical trial, expected to commence in Q4 2013; results of pre-clinical studies were presented and received with enthusiasm at two leading international meetings - the U.S. Celiac Disease Foundation's annual conference and the Digestive Disease Week conference.

Commenting on the ongoing progress within the Company's pipeline, Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, remarked, "The second quarter of 2013 has been a period of meaningful achievement for BioLineRx, in which several of our advanced products met important scientific and clinical milestones. Over the next few quarters, we will move forward on multiple exciting near-term opportunities across a number of therapeutic areas with significant unmet medical needs."

"We are eagerly awaiting completion of the CE-Mark registration trial for BL-1040 by our partner, Ikaria, which is expected to occur in 2014. We have high hopes that this unique product will become a breakthrough treatment for AMI and part of the standard of care," stated Dr. Savitsky. "For BL-5010, the CE-Mark registration trial is now slated to begin enrollment later this year, setting a clear pathway for entering the European market by the second half of 2014. The estimated worldwide market for the treatment of conditions such as seborrheic and actinic keratosis is over $500 million worldwide. We estimate that BL-5010's ease of use and low cost will allow for swift commercial acceptance, and are currently engaged in discussions with potential partners."

"We are also very pleased with the progress of the Phase 2 clinical trial for BL-8040, a best-in-class CXCR4 antagonist for the treatment of hematological cancers such as AML. We are on track to deliver partial results from the trial in the fourth quarter of 2013, with final results expected to be available by the second half of 2014."

"Another exciting opportunity for us is BL-7010, a unique product for celiac disease, a market that is projected to reach $8 billion by 2019. Despite the huge size of this market, there are no pharmacological agents approved for the treatment of celiac disease and the only treatment option is a lifelong gluten-free diet, which is extremely difficult to maintain. There are currently only four clinical-stage projects in the world in the celiac disease development pipeline, one of which is BL-7010. We expect to initiate a Phase 1/2 safety study by the end of 2013 – we have already selected the CRO and treatment sites for the study, and are in the process of preparing the necessary regulatory submissions," concluded Dr. Savitsky.

Financial Results:

During the three-month and six-month periods ended June 30, 2013 and 2012, no revenues were recorded.

Research and development expenses for the three months ended June 30, 2013 were NIS 12.1 million ($3.3 million), a decrease of NIS 3.9 million ($1.1 million), or 24%, compared to NIS 16.0 million ($4.4 million) for the three months ended June 30, 2012. The decrease resulted primarily from lower expenses in 2013 associated with the CLARITY clinical trial in respect of BL-1020, due to termination of the trial in March 2013, offset by a ramp-up in spending on other clinical-stage projects introduced during 2012. Research and development expenses for the six months ended June 30, 2013 were NIS 31.5 million ($8.7 million), an increase of NIS 0.9 million ($0.2 million), or 3%, compared to NIS 30.7 million ($8.5 million) for the comparable 2012 period. Without regard to the NIS 6.0 million one-time reversal of amounts previously accrued to the OCS in respect of BL-1020, research and development expenses increased by NIS 6.8 million ($1.9 million). The increase resulted primarily from significantly higher expenses in the 2013 period associated with the CLARITY clinical trial, as well as a ramp-up in spending on other clinical-stage projects introduced during 2012.

Sales and marketing expenses for the three months ended June 30, 2013 were NIS 1.1 million ($0.3 million), an insignificant increase compared to NIS 0.9 million ($0.3 million) for the three months ended June 30, 2012. The small increase relates to professional fees and other expenses stemming from an increase in our business development efforts, compared to the second quarter of last year. Sales and marketing expenses for the six months ended June 30, 2013 were NIS 1.8 million ($0.5 million), an insignificant increase compared to NIS 1.7 million ($0.5 million) for the comparable period in 2012. The reason for the increase is similar to the one discussed above in the three-month comparison.

General and administrative expenses for the three months ended June 30, 2013 were NIS 3.6 million ($1.0 million), an increase of NIS 0.6 million ($0.2 million), or 22%, compared to NIS 3.0 million ($0.8 million) for the three months ended June 30, 2012. The increase resulted primarily from a one-time expense for professional services incurred in the 2013 period. General and administrative expenses for the six months ended June 30, 2013 were NIS 7.1 million ($2.0 million), an increase of NIS 0.6 million ($0.2 million), or 10%, compared to NIS 6.5 million ($1.8 million) for the comparable 2012 period. The reason for the increase is similar to the one discussed above in the three-month comparison.

The Company's operating loss for the three months ended June 30, 2013 amounted to NIS 16.8 million ($4.6 million), compared with an operating loss of NIS 19.9 million ($5.5 million) for the comparable period in 2012. The Company's operating loss for the six months ended June 30, 2013 amounted to NIS 40.5 million ($11.2 million), compared with an operating loss of NIS 38.9 million ($10.7 million) for the comparable period in 2012.

The Company's net non-operating income amounted to NIS 1.6 million ($0.4 million) for the three months ended June 30, 2013, a decrease of NIS 1.1 million ($0.3 million), compared to NIS 2.7 million ($0.8 million) for the three months ended June 30, 2012. Non-operating income for both periods primarily relates to fair-value adjustments of liabilities on account of the warrants issued in the private and direct placements conducted in February 2012 and 2013. Net non-operating income amounted to NIS 13.8 million ($3.8 million) for the six months ended June 30, 2013, an increase of NIS 8.3 million ($2.3 million), compared to net non-operating income of NIS 5.5 million ($1.5 million) for the comparable 2012 period. The reason for the increase is similar to the one discussed above in the three-month comparison.

The Company recorded net financial expense of NIS 0.4 million ($0.1 million) for the three months ended June 30, 2013, a change of NIS 6.3 million ($1.7 million), compared to net financial income of NIS 5.9 million ($1.6 million) for the three months ended June 30, 2012. Net financial income and expense result primarily from changes in the average exchange rate of the dollar in relation to the NIS during the respective periods, which have a direct effect on the Company's net assets denominated in dollars. Net financial expense amounted to NIS 1.8 million ($0.5 million) for the six months ended June 30, 2013, a change of NIS 5.9 million ($1.6 million), compared to net financial income of NIS 4.1 million ($1.1 million) for the comparable 2012 period. The reason for the increase is similar to the one discussed above in the three-month comparison.

The Company's net loss for the three months ended June 30, 2013 amounted to NIS 15.6 million ($4.3 million), compared with a net loss of NIS 11.3 million ($3.1 million) for the comparable period in 2012. The Company's net loss for the six months ended June 30, 2013 amounted to NIS 28.4 million ($7.9 million), compared with a net loss of NIS 29.2 million ($8.1 million) for the comparable period in 2012.

The Company held NIS 83.5 million ($23.1 million) in cash, cash equivalents and short-term bank deposits as of June 30, 2013.

Net cash used in operating activities was NIS 41.5 million ($11.5 million) for the six months ended June 30, 2013, compared with net cash used in operating activities of NIS 36.4 million ($10.1 million) for the six months ended June 30, 2012. The NIS 5.1 million ($1.4 million) increase in net cash used in operating activities during the six-month period in 2013, versus the 2012 period, was primarily the result of increased research and development spending.

Net cash used in investing activities for the six months ended June 30, 2013 was NIS 21.4 million ($5.9 million), compared to net cash provided by investing activities of NIS 9.9 million ($2.7 million) for the six months ended June 2012. The cash flows related to investing activities primarily stem from investments in, and maturities of, short-term bank deposits during the respective periods.

Net cash provided by financing activities for the six months ended June 30, 2013 was NIS 46.0 million ($12.7 million), compared to net cash provided by financing activities of NIS 52.3 million ($14.5 million) for the six months ended June 2012. The cash flows from financing activities primarily reflect the direct and private placements completed in February 2013 and 2012.

Conference Call and Webcast Information

BioLineRx will hold a conference call to discuss its second quarter 2013 results today, August 6, 2013, at 10:00 a.m. EDT. To access the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-0609 internationally. The call will also be available via live webcast through BioLineRx's website. A replay of the conference call will be available approximately two hours after completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the U.S. or +972-3-925-5927 internationally. The replay will be available through August 9, 2013.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, and which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase 1/2 study; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has commenced a Phase 2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for schizophrenia. In addition, BioLineRx has four products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com, the content of which does not form a part of this press release.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Garth Russell / Todd Fromer
KCSA Strategic Communications
1 212-896-1250 / 1 212-896-1215 
grussell@kcsa.com / tfromer@kcsa.com

Tsipi Haitovsky
Public Relations
+972-3-6240871 
tsipih@netvision.net.il

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)





Convenience
translation into
USD


December 31,

June 30,

June 30,


2012

2013

2013


NIS in thousands

In thousands

Assets




CURRENT ASSETS




Cash and cash equivalents

68,339

50,232

13,884

Short-term bank deposits

11,459

33,238

9,187

Prepaid expenses

804

561

155

Other receivables

2,254

1,092

302

Total current assets

82,856

85,123

23,528





NON-CURRENT ASSETS




Restricted deposits

3,513

1,946

538

Long-term prepaid expenses

204

170

47

Property and equipment, net

3,172

2,871

793

Intangible assets, net

1,063

932

258

Total non-current assets

7,952

5,919

1,636

Total assets

90,808

91,042

25,164





Liabilities and equity




CURRENT LIABILITIES




Current maturities of long-term bank loan

137

-

-

Accounts payable and accruals:




Trade

12,283

15,084

4,169

OCS

6,148

-

-

Other

5,443

3,870

1,070

Total current liabilities

24,011

18,954

5,239





NON-CURRENT LIABILITIES




Retirement benefit obligations

143

143

40

Warrants

10,725

8,858

2,448

Total non-current liabilities

10,868

9,001

2,488

COMMITMENTS AND CONTINGENT LIABILITIES




Total liabilities

34,879

27,955

7,727





EQUITY




Ordinary shares

1,837

2,294

634

Share premium

464,629

498,910

137,897

Capital reserve

33,802

34,630

9,572

Accumulated deficit

(444,339)

(472,747)

(130,666)

Total equity

55,929

63,087

17,437

Total liabilities and equity

90,808

91,042

25,164









 


BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE LOSS
(UNAUDITED)





Convenience translation

into USD


Three months ended

June 30,

Six months ended

June 30,

Three months

ended
June 30,

Six months

ended
June 30,


2012

2013

2012

2013

2013

2013


NIS in thousands

In thousands

RESEARCH AND DEVELOPMENT EXPENSES,
NET

(16,000)

(12,087)

(30,675)

(31,530)

(3,341)

(8,715)

SALES AND MARKETING EXPENSES

(948)

(1,063)

(1,714)

(1,834)

(294)

(507)

GENERAL AND ADMINISTRATIVE EXPENSES

(2,956)

(3,604)

(6,481)

(7,126)

(996)

(1,970)

OPERATING LOSS

(19,904)

(16,754)

(38,870)

(40,490)

(4,631)

(11,192)

NON-OPERATING INCOME, NET

2,712

1,579

5,531

13,841

436

3,825

FINANCIAL INCOME

6,050

1,320

6,496

1,983

365

548

FINANCIAL EXPENSES

(172)

(1,713)

(2,403)

(3,742)

(473)

(1,034)

COMPREHENSIVE LOSS FOR THE PERIOD

(11,314)

(15,568)

(29,246)

(28,408)

(4,303)

(7,853)









NIS

USD








LOSS PER ORDINARY SHARE - BASIC AND
DILUTED

(0.06)

(0.07)

(0.18)

(0.13)

(0.02)

(0.04)



















 


BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)




Convenience
translation

into USD


Six months ended June 30,

Six months
ended

June 30,


2012

2013

2013


NIS in thousands

In thousands





CASH FLOWS - OPERATING ACTIVITIES




     Comprehensive loss for the period

(29,246)

(28,408)

(7,853)

     Adjustments required to reflect net cash used in operating
activities (see appendix below)

(7,178)

(13,133)

(3,629)

Net cash used in operating activities

(36,424)

(41,541)

(11,482)









CASH FLOWS - INVESTING ACTIVITIES




Investments in short-term deposits

(54,462)

(75,008)

(20,732)

Maturities of short-term deposits

64,801

52,257

14,444

Maturities of restricted deposits

-

1,550

428

Purchase of property and equipment

(431)

(132)

(36)

Purchase of intangible assets

(18)

(79)

(22)

Net cash provided by (used in) investing activities

9,890

(21,412)

(5,918)









CASH FLOWS - FINANCING ACTIVITIES




Repayments of bank loan

(149)

(127)

(35)

Issuance of share capital and warrants, net of issuance expenses

52,453

46,101

12,742

Proceeds from exercise of employee stock options

*

*

*

Net cash provided by financing activities

52,304

45,974

12,707





INCREASE (DECREASE) IN CASH AND

CASH EQUIVALENTS

25,770

(16,979)

(4,693)

CASH AND CASH EQUIVALENTS – BEGINNING

   OF PERIOD

33,061

68,339

18,889

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

4,988

(1,128)

(312)

CASH AND CASH EQUIVALENTS - END OF PERIOD

63,819

50,232

13,884





* Less than 1,000

 

BioLineRx Ltd.
APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)




Convenience
translation

into USD


Six months ended June 30,

Six months
ended

June 30,


2012

2013

2013


NIS in thousands

In thousands









Adjustments required to reflect net cash used in operating
activities:




Income and expenses not involving cash flows:




Depreciation and amortization

812

578

160

Impairment of intangible assets

-

138

38

Long-term prepaid expenses

(7)

34

9

Exchange differences on cash and cash equivalents

(4,988)

1,128

312

Share-based compensation

1,640

1,626

450

Warrant issuance costs

1,204

470

130

Gain on adjustment of warrants to fair value

(6,735)

(14,498)

(4,007)

Interest and exchange differences on short-term deposits

(641)

972

269

Interest and linkage on bank loan

(14)

(10)

(3)

Interest and exchange differences on restricted deposits

(31)

17

5


(8,760)

(9,545)

(2,637)





Changes in operating asset and liability items:




Decrease in trade accounts receivable and

       other receivables

1,668

1,405

388

Decrease in accounts payable and accruals

(86)

(4,993)

(1,380)


1,582

(3,588)

(992)


(7,178)

(13,133)

(3,629)









Supplementary information on interest received in cash

1,088

323

89











 

SOURCE BioLineRx Ltd.



RELATED LINKS
http://www.biolinerx.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release